These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 18392391)

  • 61. Levosimendan: perpetuum mobile?
    Agewall S; Atar D
    Eur Heart J; 2007 Feb; 28(4):515. PubMed ID: 17283001
    [No Abstract]   [Full Text] [Related]  

  • 62. Experience with levosimendan in 32 paediatric patients.
    Vilaboa Pedrosa C; Martínez Roca C; Yáñez Gómez P; Martín Herranz MI
    Pediatr Cardiol; 2015 Jun; 36(5):1038-41. PubMed ID: 25608697
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Levosimendan versus dobutamine in heart failure patients treated chronically with carvedilol.
    Duygu H; Turk U; Ozdogan O; Akyuz S; Kirilmaz B; Alioglu E; Gunduz R; Bozkaya YT; Turkoglu C; Payzin S
    Cardiovasc Ther; 2008; 26(3):182-8. PubMed ID: 18786088
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Assessment of sustained effects of levosimendan and dobutamine on left ventricular systolic functions by using novel tissue Doppler derived indices in patients with advanced heart failure.
    Oner E; Erturk M; Birant A; Kurtar Mansıroglu A; Akturk IF; Karakurt H; Yalcin AA; Uzun F; Somuncu MU; Yildirim A
    Cardiol J; 2015; 22(1):87-93. PubMed ID: 24846511
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [The novelty in the treatment of heart failure].
    Reingardiene D
    Medicina (Kaunas); 2005; 41(7):625-31. PubMed ID: 16062032
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Use of levosimendan for cardiogenic shock in a patient with the apical ballooning syndrome.
    De Santis V; Vitale D; Tritapepe L; Greco C; Pietropaoli P
    Ann Intern Med; 2008 Sep; 149(5):365-7. PubMed ID: 18765717
    [No Abstract]   [Full Text] [Related]  

  • 67. Effects of levosimendan on TNF-alpha, BNP and MMP-1 in patients with heart failure with anemia.
    Büyüklü M; Kürüm AT; Tatlý E; Set T
    Arq Bras Cardiol; 2012 Jul; 99(1):659-64. PubMed ID: 22735864
    [TBL] [Abstract][Full Text] [Related]  

  • 68. ST-segment elevation during levosimendan infusion.
    Barillà F; Giordano F; Jacomelli I; Pellicano M; Dominici T
    J Cardiovasc Med (Hagerstown); 2012 Jul; 13(7):454-6. PubMed ID: 22673026
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Intermittent levosimendan improves mid-term survival in chronic heart failure patients: meta-analysis of randomised trials.
    Silvetti S; Greco T; Di Prima AL; Mucchetti M; de Lurdes CM; Pasin L; Scandroglio M; Landoni G; Zangrillo A
    Clin Res Cardiol; 2014 Jul; 103(7):505-13. PubMed ID: 24368740
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Levosimendan and quality of life.
    Papadopoulos CE; Zioutas DG; Dalamaga EG
    Hellenic J Cardiol; 2010; 51(1):81-2. PubMed ID: 20118051
    [No Abstract]   [Full Text] [Related]  

  • 71. Is there a place for levosimendan in the intensive care unit?
    Simes DC
    Crit Care Resusc; 2007 Dec; 9(4):395. PubMed ID: 18052906
    [No Abstract]   [Full Text] [Related]  

  • 72. Levosimendan: a new option in acute septic cardiac failure?
    Powell BP; De Keulenaer B
    Emerg Med Australas; 2007 Apr; 19(2):177; author reply 177-8. PubMed ID: 17448109
    [No Abstract]   [Full Text] [Related]  

  • 73. A review of levosimendan in the treatment of heart failure.
    Kasikcioglu HA; Cam N
    Vasc Health Risk Manag; 2006; 2(4):389-400. PubMed ID: 17323593
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Peripartum cardiomyopathy: a new successful setting for levosimendan.
    Benezet-Mazuecos J; de la Hera J
    Int J Cardiol; 2008 Jan; 123(3):346-7. PubMed ID: 17324479
    [No Abstract]   [Full Text] [Related]  

  • 75. Medical support and surgery of the failing heart: levosimendan.
    Toller W; Knez I
    Scand J Surg; 2007; 96(2):121-4. PubMed ID: 17679353
    [No Abstract]   [Full Text] [Related]  

  • 76. [Is there a role for levosimendan in hospital emergency departments?].
    Manzano-Fernández S; Marín F; Garrido Bravo IP; Pascual Figal DA
    Rev Esp Cardiol; 2008 May; 61(5):545-6; author reply 546. PubMed ID: 18462660
    [No Abstract]   [Full Text] [Related]  

  • 77. Levosimendan for heart-operated patients: what is the state of the art?
    Tagarakis GI; Tsilimingas NB
    Recent Pat Cardiovasc Drug Discov; 2009 Jan; 4(1):22-4. PubMed ID: 19149702
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure.
    Kivikko M; Antila S; Eha J; Lehtonen L; Pentikäinen PJ
    Int J Clin Pharmacol Ther; 2002 Oct; 40(10):465-71. PubMed ID: 12395979
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Use of levosimendan for treatment of cardiogenic shock associated with electrical storm.
    Grazi M; Lauri G; Carbucicchio C; Marenzi G
    Ann Intern Med; 2009 May; 150(10):738-40. PubMed ID: 19451590
    [No Abstract]   [Full Text] [Related]  

  • 80. [Acute hemodynamic and clinical effects of a new inotropic agent, levosimendan, in patients with severe heart failure].
    Porcu M; Orrù P
    Ital Heart J Suppl; 2001 Feb; 2(2):205-6. PubMed ID: 11255888
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.